desonide
Small moleculeexperimental
Desonide (INN) is a low-potency topical corticosteroid anti-inflammatory that has been available since the 1970s. It is primarily used to treat atopic dermatitis (eczema), seborrheic dermatitis, contact dermatitis and psoriasis in both adults and children. It has a fairly good safety profile and is available as a cream, ointment, lotion, and as a foam under the tradename Verdeso Foam. Other trade names for creams, lotions, and ointments include Tridesilon, DesOwen, Desonate. It is a group VI corticosteroid under US classification, the second least potent group. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 28, 2013 (NCT03437005)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDesonide ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03758365 | Phase 1 | Nov 5, 2018 | MC2 Therapeutics |
| NCT03386032 | Phase 3 | Nov 27, 2017 | Procter and Gamble |
| NCT03437005 | Phase 1 | Jan 28, 2013 | University of California, Davis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MC2 Therapeutics | For profit | 1 | 1 | 1 | 2018 |
| Procter and Gamble | For profit | 1 | 1 | 1 | 2017 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2013 |
3 organizations
Page 1 / 1